October 2020
Financial Reports
Thermo Fisher Scientific Reports Third Quarter 2020 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 26, 2020...
Thermo Fisher Scientific Reports Third Quarter 2020 Results >
July 2020
Financial Reports
Thermo Fisher Scientific Reports Second Quarter 2020 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 27, 2020....
Thermo Fisher Scientific Reports Second Quarter 2020 Results >
April 2020
Financial Reports
Thermo Fisher Scientific Reports First Quarter 2020 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2020....
Thermo Fisher Scientific Reports First Quarter 2020 Results >
January 2020
Financial Reports
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2019 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2019...
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2019 Results >
News Archive
2019
November 2019
Copeptin / Cardiology
Copeptin now in the new European Society of Cardiology Guidelines for the Diagnosis and Treatment of Pulmonary Embolism 2019
Acute pulmonary embolism is one of the leading causes for cardiovascular death worldwide. Clinicians can now rely on copeptin as a prognostic biomarker for the risk stratification of patients with acute pulmonary embolism, which was recently included in the new guideline from the European Society of Cardiology (ESC) for the diagnosis and treatment of acute pulmonary embolism.
October 2019
Financial Reports
Thermo Fisher Scientific Reports Third Quarter 2019 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2019.
Thermo Fisher Scientific Reports Third Quarter 2019 Results >
August 2019
Procalcitonin (PCT)
Success for Brahms as Radiometer’s nullity suit dismissed
Patent holder Brahms has won the next round in the long-standing dispute over procedures for detecting infections. The Federal Patent Court has dismissed a nullity suit from Radiometer
Read the news on JUVE Patent >
July 2019
Procalcitonin (PCT)
Validity of B·R·A·H·M·S’ patent confirmed by German Federal Patent Court
Again, B·R·A·H·M·S GmbH (B·R·A·H·M·S) has successfully defended one of its many patents relating to Procalcitonin (PCT) in diagnostics and therapy around sepsis and infectious diseases. In a judgment pronounced on 23 July 2019, the German Federal Patent Court confirmed the validity of the German part of B·R·A·H·M·S’ European patent (EP 2 301 626 B1), and completely rejected a revocation action instigated by Radiometer GmbH and Radiometer Medical ApS.
B·R·A·H·M·S’ patent relates to the use of antibiotics in the treatment of a specific group of patients having defined PCT levels. The broad protection conferred by this patent is justified by the fundamental and innovative nature of the patented invention, which has been recognized and acknowledged by the Federal Patent Court’s in its decision to maintain the patent as granted. Because of this the Court held Radiometer liable to pay all court fees and to reimburse the attorney’s fees incurred by B·R·A·H·M·S for its successful defense.
B·R·A·H·M·S welcomes this decision and continues to vigorously defend and enforce its patent rights relating to PCT in Germany and worldwide.
July 2019
Financial Reports
Thermo Fisher Scientific Reports Second Quarter 2019 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29, 2019.
Thermo Fisher Scientific Reports Second Quarter 2019 Results >
May 2019
Procalcitonin / Health Economics
U.S. Health Economic Analysis Demonstrates the Cost Reduction Impact of using B·R·A·H·M·S PCT to Support Antibiotic Stewardship Versus Standard of Care
Outcome shows a reduction in antibiotic days, shorter length of stay, shorter duration of mechanical ventilation, and fewer patients at risk for antibiotic resistance or C.difficile infection lead to incremental reduction of costs of 26 percent in sepsis and 17.7 percent in lower respiratory tract infection
May 2019
Copeptin / Registration
The novel blood biomarker Copeptin is now available for clinical use in early rule-out of acute myocardial infarction and diagnosing water balance disorders
B·R·A·H·M·S Copeptin proAVP KRYPTOR has been registered in Canada allowing for faster, more reliable indirect measurement of vasopressin to improve diagnostic algorithms
May 2019
Copeptin / Research
European Endocrinology Award 2019 for research about Copeptin
Prof. Christ-Crain gave a lecture on “New diagnostic approaches in the diagnosis of Diabetes insipidus” at the opening ceremony of the ECE 2019, because she received the European Endocrinology Award 2019 for her research about Copeptin.
May 2019
Sepsis / Emergency Department (ED)
New Study Results Find That The Blood Biomarker MR-proADM May Prevent Early Hospital Discharge in Patients with Developing Sepsis
Multi-centre analysis shows that incorporation of MR-proADM (mid-regional proadrenomedullin) into an early management of patients with suspected infection protocol may aid rapid clinical decision making in the emergency department
May 2019
Prenatal screening
World Pre-eclampsia Day on May 22nd
May is Pre-eclampsia awareness month and May 22nd is World Pre-eclampsia Day: Thermo Fisher Scientific proudly supports the pre-eclampsia awareness campaign 2019 organized by EFCNI (European Foundation for the Care of Newborn Infants).
Learn more about World Pre-eclampsia Day >
Pre-eclampsia: First trimester screening >
April 2019
Financial Reports
Thermo Fisher Scientific Reports First Quarter 2019 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2019.
Thermo Fisher Scientific Reports First Quarter 2019 Results >
January 2019
Financial Reports
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2018 Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2018.
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2018 Results >
2018
Thermo Fisher Scientific Declares Quarterly Dividend
November 8, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per common share...
Thermo Fisher Scientific Declares Quarterly Dividend >
Thermo Fisher Scientific Showcases Innovations for Research and Clinical Labs at AACC 2018
July 31, 2018
AACC -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is showcasing its latest innovations for clinical and translational research during the 2018 American...
Thermo Fisher Scientific Showcases Innovations for Research and Clinical Labs at AACC 2018 >
Thermo Fisher Scientific Reports Second Quarter 2018 Results
July 25, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 30, 2018. Second Quarter 2018 Highlights Grew...
Thermo Fisher Scientific Reports Second Quarter 2018 Results >
New Thermo Scientific B·R·A·H·M·S PCT direct blood test allows fast bacterial infection and sepsis diagnosis at patient’s point of care
July 17, 2018
The new B·R·A·H·M·S PCT direct point of care assay requires just one drop of blood for a reliable infection diagnosis and clinical decisions in the acute care setting within 20 minutes.
New Thermo Scientific B·R·A·H·M·S PCT direct blood test allows fast bacterial infection and sepsis diagnosis at patient’s point of care >
Thermo Fisher Scientific Declares Quarterly Dividend
July 13, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per common share...
Thermo Fisher Scientific Declares Quarterly Dividend >
Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis
July 13, 2018
Elecsys® B·R·A·H·M·S PCT™ (procalcitonin) helps clinicians assess presence and severity of certain bacterial infections and patient response to antibiotics
Roche PCT assay cleared for expanded use - Important tool in antibiotic resistance crisis >
10th International Workshop on Prenatal Screening
June, 2018
The 10th International Workshop on Prenatal Screening, organized by Thermo Fisher Scientific, took place in Berlin. Almost 170 participants from 28 countries attended the workshop. As already in the previous years the highly scientific program with internationally well recognized speakers makes it a much appreciated event on prenatal screening. For further information about lectures and speakers please get in contact with us.
Contact us >
Read more on prenatal screening >
New Thermo Scientific B·R·A·H·M·S KRYPTOR GOLD Analyzer Instrument Combines Higher Throughput and Maximum Autonomy
June 15, 2018
New KRYPTOR GOLD instrument features the precision and productivity required for clinical specialty diagnostics laboratories and patient diagnosis and prognosis research
Read the News Press Release here >
Find more about B·R·A·H·M·S KRYPTOR GOLD >
Thermo Fisher Scientific supports the European STATIN trial to evaluate pravastatin in the potential prevention of preeclampsia
June 5, 2018
Research results suggest a preventive role of statins in the late-onset form of preeclampsia
Read the News Press Release here >
Thermo Fisher Scientific Supports World Preeclampsia Day on May 22
May, 2018
May 2018 is the pre-eclampsia awareness month with World Preeclampsia Day happening on May 22. Pre-eclampsia is a rare and severe pregnancy complication affecting about 2-8% of pregnancies worldwide. Thermo Fisher Scientific is proud to support this important initiative to create awareness about the symptoms and risks of this disease, but also to inform about the benefits of an early screening test which can be an advise for possible preventive measures and possible prevention in order to improve pregnancy outcome.
EFCNI (European Foundation for the Care of Newborn Infants) >
Thermo Fisher Scientific Reports First Quarter 2018 Results
April 25, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 31, 2018.
Thermo Fisher Scientific Reports First Quarter 2018 Results >
New Publication: The use of MR-proADM in assessing disease severity and treatment response in patients with sepsis and septic shock
March 26, 2018
In collaboration with the SepNet Critical Care Trials Group, a new analysis of 1089 patients with sepsis and septic shock across 33 German Intensive Care Units was recently published in Critical Care. MR-proADM could add significant value to identifying patients at risk of further disease progression, the earlier escalation of therapy in patients at risk of treatment failure, and the subsequent de-escalation of treatment and early discharge of low risk patients.
Read the News Press Release here >
Read the full publication here >
Thermo Fisher Scientific Increases Quarterly Dividend
January 31, 2018
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors has authorized a quarterly cash dividend of $0.17 per common share, payable on April 16, 2018, to shareholders of record as of March 15, 2018. This reflects a 13% increase over the previous dividend payment of $0.15.
Thermo Fisher Scientific Increases Quarterly Dividend >
2017
Thermo Fisher Scientific Declares Quarterly Dividend
October 25, 2017
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 30, 2017.
Thermo Fisher Scientific Declares Quarterly Dividend >
Ortho Clinical Diagnostics Announces Global Agreement to Make B·R·A·H·M·S PCT Assay Available to Ortho Customers
Jul 31, 2017
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced a strategic relationship with B·R·A·H·M·S GmbH, part of Thermo Fisher Scientific Inc., to develop the B·R·A·H·M·S PCT (Procalcitonin) assay for use on Ortho's VITROS® Systems.
Assay plays key role in aiding clinicians in the assessment and treatment of sepsis and septic shock >
Thermo Fisher Scientific Declares Quarterly Dividend
May 18, 2017
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share.
Thermo Fisher Scientific Declares Quarterly Dividend >
Multi-Center Clinical Study Confirms Decreased Levels of Procalcitonin as an Independent Predictor of Mortality in Patients with Severe Sepsis and Septic Shock
April 20, 2017
Results from Procalcitonin MOnitoring SEpsis Study published in May 2017 issue of Critical Care Medicine
Multi-Center Clinical Study Confirms Decreased Levels of Procalcitonin as an Independent Predictor of Mortality in Patients with Severe Sepsis and Septic Shock >
Thermo Fisher Scientific Declares Quarterly Dividend
February 28, 2017
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share.
Thermo Fisher Scientific Declares Quarterly Dividend >
2016
B·R·A·H·M·S GmbH, Teil von Thermo Fisher Scientific, gibt die Aufnahme von Copeptin in die Empfehlungen der Deutschen Gesellschaft für Kardiologie (DGK) bekannt (German)
December 06, 2016
DGK folgt den Empfehlungen der ESC Guidelines für den sofortigen Ausschluss eines akuten Myokardinfarkts (AMI) mittels Kombination aus Copeptin und Troponin; legt den Einsatz für niedergelassene Kardiologen fest.
Copeptin in den Empfehlungen der Deutschen Gesellschaft für Kardiologie (DGK) >
B·R·A·H·M·S GmbH, part of Thermo Fisher Scientific, Announces Copeptin Now Included in the German Cardiac Society (DGK) Recommendations (English translation from German press release)
Copeptin in DGK recommendations (English translation) >
Thermo Fisher Scientific Declares Quarterly Dividend
November 10, 2016
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share.
Thermo Fisher Scientific Declares Quarterly Dividend >
Thermo Fisher Scientific Joins Sepsis Alliance in Support of Sepsis Awareness Month
September 26, 2016
Thermo Fisher Scientific announces its support of the Sepsis Alliances’ Sepsis Awareness Month to drive awareness around sepsis, a complex clinical syndrome and a leading cause of death in ICUs globally.
Thermo Fisher Scientific Joins Sepsis Alliance >
Thermo Fisher Scientific Declares Quarterly Dividend and Authorizes $1.5 Billion of Share Repurchases
July 07, 2016
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors declared a quarterly cash dividend of $0.15 per share.
Thermo Fisher Scientific Declares Quarterly Dividend >
Innovative trial design helps accelerate FDA clearance process for B·R·A·H·M·S PCT license partners
July 07, 2016
An innovative trial design helped our license partners, Roche Diagnostics USA and bioMérieux, achieve FDA clearance in just 90 days for the Roche ELECSYS B·R·A·H·M·S PCT and bioMérieux VIDAS B·R·A·H·M·S PCT assays. The Procalcitonin MOnitoring SEpsis Study (MOSES) included 858 adult patients with sepsis recruited across 13 investigational sites in the U.S.
B·R·A·H·M·S PCT license partners achieve FDA clearance in 90 days >
Thermo Fisher Scientific Declares Quarterly Dividend
May 18, 2016
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has declared a quarterly cash dividend of $0.15 per share.
Thermo Fisher Scientific Declares Quarterly Dividend >
Expanded FDA clearance for B·R·A·H·M·S PCT sepsis biomarker
March 01, 2016
Thermo Fisher Scientific Inc. has received clearance from the U.S. Food and Drug Administration (FDA) that expands the clinical claims of the Thermo Scientific B·R·A·H·M·S PCT (Procalcitonin) biomarker assay for sepsis risk assessment. Clinicians can now use B·R·A·H·M·S PCT to help assess the response of septic patients to treatment by comparing a baseline PCT measurement with a PCT value taken on day four.
B·R·A·H·M·S PCT cleared for assessing mortality risk of septic patients >
Thermo Fisher Scientific Reports Record Fourth Quarter and Full Year 2015 Results
January 28, 2016
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2015.
Thermo Fisher Scientific Reports Record Fourth Quarter and Full Year 2015 Results >
New B·R·A·H·M·S PCT Testing Solution in Europe for the Samsung IB10 Point-of-Care Platform
January 25, 2016
For healthcare professionals facing the complexity of daily requirements in emergency situations, a new point-of-care test, Samsung IB B·R·A·H·M·S PCT assay, offers an integrated solution for accurate sepsis diagnosis and antibiotic stewardship. The test, which recently received a CE mark for use in Europe, may further improve medical decision-making about risk assessment and therapy management.
Read more about the Samsung IB B·R·A·H·M·S PCT biomarker assay >
